Drug repurposing
Finding new therapeutic uses for drugs already approved for something else — skipping the early safety work because it was already done.
A drug approved for one disease carries years of safety and pharmacology data. Repurposing asks whether that same molecule treats a different condition — cutting the path from hypothesis to human trial from decades to years. The hard part is incentive: a drug already off-patent earns no exclusivity period, so there is little commercial return to fund the trials, even when the biology is promising. That structural gap is why genuinely useful repurposed drugs often stay unprescribed long after the evidence appears.
Where it came from
In megatrends
Related players
Finds citing this concept
Overall = breadth + depth + substance + ½·novelty + freshness (a small boost that halves each week)
Every Cure
A nonprofit's AI now ranks every FDA-approved drug against every known disease in one overnight run, and has committed to publishing the whole table for free.
The unpatentable cure
A 2023 Indian trial found that a squirt of cheap generic lidocaine around a breast tumor, minutes before surgery, cut five-year deaths by nearly a third — and almost no one outside India adopted it.
How this connects
Tap a node to open it